04:56 PM EST, 11/11/2024 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) reported a Q3 net loss late Monday of $1.13 per diluted share, widening from $0.57 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.83.

Cash, cash equivalents and investments as of Sept. 30 were $263.6 million, up from $239 million as of Dec. 31, 2023.

Mineralys said it expects current cash, cash equivalents and investments to fund clinical trials and corporate operations into 2026.